Your browser doesn't support javascript.
loading
Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
Chapple, C R; Abrams, P; Andersson, K-E; Radziszewski, P; Masuda, T; Small, M; Kuwayama, T; Deacon, S.
Afiliación
  • Chapple CR; Royal Hallamshire Hospital, Sheffield, United Kingdom. Electronic address: c.r.chapple@sheffield.ac.uk.
  • Abrams P; Southmead Hospital, Bristol Urological Institute, Bristol, United Kingdom.
  • Andersson KE; Wake Forest University School of Medicine, Winston-Salem, North Carolina.
  • Radziszewski P; Department of Urology, Medical University of Warsaw, Warsaw, Poland.
  • Masuda T; ONO Pharma Ltd., London, United Kingdom.
  • Small M; ONO Pharma Ltd., London, United Kingdom.
  • Kuwayama T; ONO Pharma Ltd., London, United Kingdom.
  • Deacon S; ONO Pharma Ltd., London, United Kingdom.
J Urol ; 191(1): 253-60, 2014 Jan.
Article en En | MEDLINE | ID: mdl-24018240

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenilpropanolamina / Compuestos de Bencidrilo / Cresoles / Vejiga Urinaria Hiperactiva / Subtipo EP1 de Receptores de Prostaglandina E / Agentes Urológicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Urol Año: 2014 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenilpropanolamina / Compuestos de Bencidrilo / Cresoles / Vejiga Urinaria Hiperactiva / Subtipo EP1 de Receptores de Prostaglandina E / Agentes Urológicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Urol Año: 2014 Tipo del documento: Article